Gabrielle Nayroles, M.Sc.
Director, Market Access
As a Director in the Market Access team, Gabrielle is responsible for conducting market access analyses and providing recommendations and input to client development plans, early access challenges, and due diligence activities.
Since joining VCLS, Gabrielle has worked closely with clients across a wide range of health technologies, including orphan drugs, advanced therapies, repurposed drugs, and has developed an expertise in ultra-rare diseases, cystic fibrosis, retinitis pigmentosa, hematopoietic cell transplantation, and antibiotic resistance.
She brings 20-years of experience from having worked in different business cultures in a variety of global market access positions in both pharmaceutical and biotech companies. This includes more than 6 years of working in the field of rare diseases.
Gabrielle started her market access career in 1999 at Lundbeck. As a global pricing and reimbursement manager, she was responsible for Lundbeck’s mood disorder portfolio (Cipramil, Cipralex) and worked on neurology assets (desmoteplase, Azilect, Ebixa, Circadin). In this role, she contributed to a number of value dossiers and was responsible for formulating the defense of Cripalex price, leveraging price differentiation, benchmark analyses, and expertise gained in European policies and pricing rules. She was also responsible for evaluating pricing and reimbursement potential in life-cycle management and for business development opportunities.
Gabrielle subsequently joined Ipsen in 2012 as global market access and pricing director for rare diseases, for a joint venture in hemophilia with the US-based start-up Inspiration Biopharmaceutical Inc. She developed European market access strategy plans for Ixinity and Obizur (for hemophilia B and acquired Factor VIII deficiency respectively) and presented them to buyers when assets were sold.
She also successfully developed and lead pricing and reimbursement strategies for Somatuline antitumor indication (neuroendocrine tumors) and for the orphan drug Xermelo (carcinoid syndrome diarrhea).
During this time, Gabrielle successfully negotiated double-digit price increases in Europe and Turkey for Increlex and Somatuline. She also contributed to various life-cycle management, business development opportunities, and publications in acromegaly, neuroendocrine tumors, Cushing syndrome, short-stature, Huntington’s disease, multiple sclerosis, dermatology, urology, and rare cancers.
Gabrielle holds Bachelor of Arts in Psychology, in Business Information from the University of Rouen, a Masters in Competitive Intelligence from the University of Marne-la-Vallée, as well as HEOR training from the CNAM in Paris and a European Market Access University Diploma (EMAUD) from Lyon.
She has been a lecturer at EMAUD since 2012.
Gabrielle speaks English and French and is based in our Boulogne office in France.